Skip to main content

Table 1 Characteristics of the 17 RCTs included in the meta-analysis of ICSs and risk of URTI

From: Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

Study Duration (months) Mean Age (years) FEV1 (%predicted) Male (%) Interventions NO. of URTI/Total
Mahler et al. [13] 5.5 63.5 40.8 66.0 T:FP 500 μg bid or FSC (S 50 μg /FP 500 μg) bid T:84/342
C: Placebo or S 50 μg bid C: 56/349
Hanania et al. [22] 5.5 63.8 41.8 63.2 T:FP 250 μg bid or FSC (S 50 μg /FP 250 μg) bid T:40/361
C: Placebo or S 50 μg bid C: 42/362
Calverley et al. [11] 36 65.0 44.0 75.5 T:FP 500 μg bid or FSC (S 50 μg /FP 500 μg) bid T:309/3098
C: Placebo or S 50 μg bid C: 277/3086
Zheng et al. [23] 5.5 66.2 47.0 89.2 T:FSC (S 50 μg /FP 500 μg) bid T:32/297
C: Placebo C: 14/148
Ferguson et al. [24] 12 65.0 32.8 55.0 T:FP 250 μg bid T:31/394
C: S 50 μg bid C: 31/388
Calverley et al. [25] 12 65.1 NR 68.3 T: MF 800 μg qd or MF 400 μg bid T:164/616
C: Placebo C: 71/295
Anzueto et al. [26] 12 65.4 34 54.0 T:FSC (S 50 μg /FP 500 μg) bid T:41/394
C: Placebo C: 30/403
Calverley et al. [27] 11 63.6 42.2 80.7 T:BDP/FM 200/12 μg bid or BUD/FM 400/12 μg bid T:3/479
C: FM 12 μg bid C: 5/239
Tashkin et al. [30] 6 59.8 NR 77.5 T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid T:19/634
C: Placebo or FM 10 μg bid C:13/421
Tashkin et al. [16] 12 59.7 39.1 76.0 T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid T:58/1351
C: Placebo or FM 10 μg bid C: 39/900
Doherty et al. [29] 6 59.6 38.6 75.2 T: MF/FM 200/10 μg bid or MF/FM 400/10 μg bid or MF 400 μg bid T:39/717
C: Placebo or FM 10 μg bid C: 26/479
Sharafkhaneh et al. [12] 12 63.0 37.7 62.0 T:BUD/FM 320/9 μg bid or BUD/FM 160/9 μg bid T:90/815
C: FM 9 μg bid C: 39/403
Boscia et al. [28] 1 57.9 49.8 46.3 T:FF/VI 50/25 μg qd or FF/VI 100/25 μg qd or FF/VI 200/25 μg qd T:2/98
C: Placebo C: 1/51
Vogelmeier et al. [15] 6 63.3 60.3 70.9 T: FSC (S 50 μg /FP 500 μg) bid T:2/264
C: QVA149 110/50 μg qd C: 7/258
Kerwin et al. [14] 5.5 62.5 48.3 66.6 T:FF/VI 50/25 μg qd or FF/VI 100/25 μg qd or FF 100 μg qd T:50/618
C: Placebo or VI 25 μg qd C: 19/412
Martinez et al. [17] 5.5 61.5 47.9 72.3 T:FF/VI 100/25 μg qd or FF/VI 200/25 μg qd or FF 100 μg qd or FF 200 μg qd T:23/816
C: Placebo or VI 25 μg qd C: 14/408
Huang et al. [31] 2.8 64.1 NR 86.4 T: BUD/FM 320/9 μg bid, I 40 μg qid and T 100 mg bid T:4/293
C:I 40 μg qid and Th 100 mg bid C: 2/289
  1. Abbreviations: ICSs Inhaled corticosteroids, URTI Upper respiratory tract infection, FEV1 Forced expiratory volume in 1 s, T Treatment group, C Control group, NR Not reported, FP Fluticasone propionate, S Salmeterol, FSC Fluticasone propionate/salmeterol, P Placebo, MF Mometasone furoate, BUD Budesonide, FM Formoterol, BDP Beclomethasone, QVA149 Indacaterol/glycopyrronium, FF Fluticasone furoate, VI Vilanterol, I Ipratropium, Th Theophylline, QD Once a day, BID Twice a day, QID Four times a day